823-89-2

Basic information

• Product Name: 5-BROMO-2-HYDRAZINOPYRIMIDINE
• Synonyms: (5-BROMO-PYRIMIDIN-2-YL)HYDRAZINE;5-BROMO-2-HYDRAZINOPYRIMIDINE;2-(5-broMopyriMidin-2-yl)hydrazine;5-Bromo-2-hydrazino-1,3-diazine, (5-Bromopyrimidin-2-yl)hydrazine;(5-Bromopyrimidin-2-yl)hydrazine(HCl);(5-bromo-2-pyrimidinyl)hydrazine
• CAS NO: 823-89-2
• Molecular Formula: C₄H₅BrN₄
• Molecular Weight: 189.01
• Product Categories: Organohalides;Pyrimidine;Heterocycle-Pyrimidine series
• Mol File: 823-89-2.mol
• Article Data: 5

Chemical Properties

• Melting Point: 205-207(dec.)
• Boiling Point: 354.7ºC at 760 mmHg
• Flash Point: 168.3ºC
• Appearance: /
• Density: 1.915g/cm3
• Vapor Pressure: 3.29E-05mmHg at 25°C
• Refractive Index: 1.711
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 5.42±0.20(Predicted)
• CAS DataBase Reference: 5-BROMO-2-HYDRAZINOPYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-HYDRAZINOPYRIMIDINE(823-89-2)
• EPA Substance Registry System: 5-BROMO-2-HYDRAZINOPYRIMIDINE(823-89-2)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 823-89-2(Hazardous Substances Data)

Usage

General Description

5-Bromo-2-hydrazinopyrimidine is a chemical compound with the molecular formula C4H5BrN4. It is a hydrazine and pyrimidine derivative that is commonly used in pharmaceutical and research applications. 5-BROMO-2-HYDRAZINOPYRIMIDINE is primarily used as a building block in the synthesis of various pharmaceutical compounds and is often employed as a reagent in organic synthesis. Its hydrazine functional group makes it a versatile precursor in the development of various drug molecules and other organic compounds. Additionally, 5-Bromo-2-hydrazinopyrimidine is also utilized in the research and development of new chemical entities and other scientific applications due to its unique chemical properties.

InChI:InChI=1/C4H5BrN4/c5-3-1-7-4(9-6)8-2-3/h1-2H,6H2,(H,7,8,9)

Upstream product

• 32779-36-5 5-Bromo-2-chloropyrimidine 

Downstream Products

• 1272659-59-2 (E)-2-(3-acetylbenzylidene)-1-(5-bromopyrimidin-2-yl)hydrazine 
• 1272659-58-1 (E)-2-(4-methoxybenzylidene)-1-(5-bromopyrimidin-2-yl)hydrazine 
• 1272659-60-5 (E)-2-(4-carboxybenzylidene)-1-(5-bromopyrimidin-2-yl)hydrazine 
• 1272659-62-7 (E)-2-(3,4-dimethoxybenzylidene)-1-(5-bromopyrimidin-2-yl)hydrazine 
• 1312952-12-7 (E)-2-(2-benzylidenehydrazinyl)-5-bromopyrimidine 
• 1233537-70-6 5-bromo-2-(5-(4-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)pyrimidine 
• 1400673-85-9 5-bromo-2-(3-phenyl-5-p-tolyl-4,5-dihydro-1H-pyrazol-1-yl)pyrimidine 
• 1400673-87-1 5-bromo-2-(5-(4-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)pyrimidine 
• 1400673-89-3 5-bromo-2-(5-(4-bromophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)pyrimidine 
• 1400673-91-7 2-(3,5-bis(4-bromophenyl)-4,5-dihydro-1H-pyrazol-1-yl)-5-bromopyrimidine 
• 1400673-93-9 5-bromo-2-(3-(4-bromophenyl)-5-p-tolyl-4,5-dihydro-1H-pyrazol-1-yl)pyrimidine 
• 1400673-95-1 5-Bromo-2-(3-(4-bromophenyl)-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)pyrimidine 
• 1400673-97-3 5-bromo-2-(3-(4-chlorophenyl)-5-p-tolyl-4,5-dihydro-1H-pyrazol-1-yl)pyrimidine 
• 1400673-99-5 5-bromo-2-(3-(4-chlorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl)pyrimidine 

Relevant articles and documents

Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis

There is an urgent need for new treatments for visceral leishmaniasis (VL), a parasitic infection which impacts heavily large areas of East Africa, Asia, and South America. We previously reported on the discovery of GSK3494245/DDD01305143 (1) as a preclinical candidate for VL and, herein, we report on the medicinal chemistry program that led to its identification. A hit from a phenotypic screen was optimized to give a compound with in vivo efficacy, which was hampered by poor solubility and genotoxicity. The work on the original scaffold failed to lead to developable compounds, so an extensive scaffold-hopping exercise involving medicinal chemistry design, in silico profiling, and subsequent synthesis was utilized, leading to the preclinical candidate. The compound was shown to act via proteasome inhibition, and we report on the modeling of different scaffolds into a cryo-EM structure and the impact this has on our understanding of the series' structure-activity relationships.

Synthesis, characterization and pharmacological study of 4,5-dihydropyrazolines carrying pyrimidine moiety

A series of 5-bromo-2-(3,5-diaryl-4,5-dihydro-1H-pyrazol-1-yl)pyrimidine were prepared under conventional heating as well as microwave reaction condition. The newly synthesized compounds were characterized on the basis of elemental, spectral and single crystal X-ray studies. These new compounds were screened for their antioxidant, anti-inflammatory and analgesic activities. Some of these compounds exhibited potent biological activities compared to the standard drug.

Substituted Triazolo-Pyrimidine Compounds

The present invention relates to substituted triazolo-pyrimidine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted triazolo-pyrimidine compounds and methods of t